[
  {
    "ts": null,
    "headline": "Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010",
    "summary": "In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile. This move marks a key test of Moderna’s effort to extend its mRNA platform beyond COVID-19, potentially broadening its respiratory vaccine portfolio and reducing reliance on a single product...",
    "url": "https://finnhub.io/api/news?id=14ec86acacde05a5a8f66dc00a80b2d20eb456fe9656a16b2a014aa83998329a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767921002,
      "headline": "Moderna (MRNA) Is Up 14.8% After Filing Global Applications For Its mRNA Flu Vaccine mRNA-1010",
      "id": 138043636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 in the US, EU, Canada, and Australia for adults aged 50 and older, supported by positive Phase 3 data showing relative vaccine efficacy of about 27% and a favorable safety profile. This move marks a key test of Moderna’s effort to extend its mRNA platform beyond COVID-19, potentially broadening its respiratory vaccine portfolio and reducing reliance on a single product...",
      "url": "https://finnhub.io/api/news?id=14ec86acacde05a5a8f66dc00a80b2d20eb456fe9656a16b2a014aa83998329a"
    }
  }
]